What is tesamorelin?

A growth hormone drug, not an appetite drug

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary gland to release its own growth hormone. Instead of injecting growth hormone directly, tesamorelin tells the pituitary to make more of it. That distinction matters clinically: it works only as long as the pituitary can still respond, and it raises growth hormone and IGF-1 within something closer to a natural pulsatile pattern rather than flooding the body with an external hormone.

More growth hormone drives lipolysis, the breakdown of stored fat, and tesamorelin's effect turns out to be concentrated almost entirely in visceral fat, the fat packed around the liver, intestines, and other organs, rather than the fat under the skin. That is a specific and clinically useful effect. It is also a completely different mechanism from the incretin pathway that semaglutide and tirzepatide use to suppress appetite and drive total body weight loss.

What the FDA actually approved

The FDA approved tesamorelin in 2010 under the brand name Egrifta, for one specific purpose: reducing excess abdominal fat in HIV-infected adults with lipodystrophy, a condition where HIV and some of its treatments cause fat to redistribute abnormally, building up around the organs while wasting away elsewhere. The original formulation was replaced by Egrifta SV in 2019, and a newer version, Egrifta WR, won approval in March 2025. The WR formulation needs only weekly reconstitution instead of daily, which is a meaningful quality-of-life difference for a drug taken by injection every day.

Nowhere in that approval history is general weight loss, body recomposition, or anti-aging. Marketing copy for tesamorelin as a fat-loss peptide for people without HIV is describing an off-label use, not the approved indication.

The trial data behind the approval

The pivotal study, led by Julian Falutz and published in the New England Journal of Medicine in 2007, randomized 412 adults with HIV and visceral fat accumulation to a daily 2mg tesamorelin injection or placebo for 26 weeks.

A later trial found the visceral fat reduction came with a secondary benefit: measurable improvement in liver enzymes, consistent with less fat infiltrating the liver as visceral fat dropped. That is a real, replicated effect. It is also an effect measured exclusively in people with HIV-associated lipodystrophy, a population with a specific pattern of fat gain that does not necessarily generalize to someone trying to lose ordinary visceral fat without that underlying condition.

Why people without HIV are buying it anyway

Off-label prescribing is legal. A licensed physician can prescribe an FDA-approved drug for a use outside its label if they judge it appropriate for the patient in front of them, and a growing number of telehealth peptide and longevity clinics do exactly that, prescribing tesamorelin to people without HIV for general visceral fat reduction or as an add-on to a GLP-1 regimen. That is different from BPC-157 or other research peptides bought from gray-market vendors with no prescription and no oversight at all. Tesamorelin sold through a licensed prescriber and a registered pharmacy is a real, quality-controlled drug.

What it is not is evidence-backed for that specific use. Every efficacy number in this article comes from HIV-associated lipodystrophy patients. Nobody has published a large randomized trial testing tesamorelin for visceral fat reduction in people without HIV. It may well work similarly. It also may not, since lipodystrophy involves a distinct hormonal and metabolic profile. Anyone considering it off-label should treat the 15 to 18% figure as what happened in that trial population, not a guarantee.

Tesamorelin versus GLP-1s: different jobs

The comparison people actually want to make is against semaglutide or tirzepatide, and the honest answer is that they are not solving the same problem. GLP-1 drugs suppress appetite through the incretin system and drive total body weight loss, commonly 15 to 22% of starting body weight in trials. Tesamorelin does not touch appetite or overall calorie intake. It raises growth hormone, which drives fat loss concentrated in the visceral depot, with a much smaller effect on total body weight or subcutaneous fat.

That is why some clinics pitch the two as complementary rather than competing: a GLP-1 for overall weight, tesamorelin layered on for the visceral fat a GLP-1 alone may not fully clear, similar in spirit to how peptides get stacked for other goals. It is a reasonable hypothesis. It is still a hypothesis. No published trial has tested tesamorelin plus a GLP-1 head-to-head against a GLP-1 alone.

Side effects and who should avoid it

The FDA label carries a warning worth taking seriously: tesamorelin raises IGF-1, and elevated IGF-1 is associated with tumor growth, so it is contraindicated in anyone with active malignancy and needs careful evaluation in anyone with a cancer history. In trials, clinically meaningful blood sugar elevation, HbA1c at or above 6.5%, showed up in about 5% of tesamorelin patients versus 1% on placebo, a hazard ratio of roughly 3.3, so glucose monitoring matters, particularly for anyone with diabetes risk factors.

The most common side effects in trials were joint and muscle pain, redness or itching at the injection site, swelling, and pain in the arms or legs. It is contraindicated in pregnancy, where animal studies showed fetal harm at higher doses, and in anyone with a pituitary tumor or a history of head irradiation, since the drug works directly on pituitary function.

Cost: brand versus compounded

Brand-name Egrifta SV and Egrifta WR are expensive, commonly running into the thousands of dollars per month at list price before insurance, and insurers generally only cover it for the approved HIV-lipodystrophy indication. Compounded tesamorelin, prepared by a 503A or 503B pharmacy from bulk material rather than the branded product, is the version most off-label users encounter through telehealth peptide clinics, at a small fraction of the brand price. Compounded does not mean unregulated. A 503B outsourcing facility operates under FDA oversight and current good manufacturing practice rules, similar to how compounding pharmacies supply compounded GLP-1s. It does mean the specific batch was not the one tested in the pivotal trials, so sourcing from a legitimate, licensed facility matters more than it would for a brand-name fill.